A signal-finding study of nivolumab and relatlimab in patients with advanced chordoma.

作者
Aaron Burkenroad,Arun S. Singh,Bartosz Chmielowski,Sandra Brackert,Noah C. Federman,Anahis Hagopian,John A. Glaspy,Joseph Keith Kendal,Lauren Elisabeth Wessel,Francis John Hornicek,Nicholas Matthew Bernthal
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 11578-11578 被引量:3
标识
DOI:10.1200/jco.2024.42.16_suppl.11578
摘要

11578 Background: Chordomas are derived from notochordal remnants and are typically treated with surgery and radiation therapy. For advanced chordomas, there are no approved systemic therapies. Preclinical evidence and anecdotal reports have indicated that the immune system is active in chordomas and that there may be a role for immunomodulation in treating this disease. Methods: This study is a single-arm, signal-finding trial in patients with advanced chordoma treated with the anti PD-1 antibody nivolumab (480 mg Q4 weeks up to 2 years) and the anti-LAG3 antibody relatlimab (160 mg Q4 weeks up to 2 years). The primary objective of this study was to assess the safety of nivolumab and relatlimab in subjects with progressive metastatic or locally advanced/unresectable chordoma. Secondary objectives were to ascertain the median progression free survival (PFS), response rate (RR), and the 4- and 6-month PFS by RECIST 1.1. Results: Out of a planned enrollment of 20 patients, 10 patients (8 Male, 2 Female) were consented and treated on trial. Enrolled patients had the following sites of involvement: 5 clival/c-spine, 4 sacral, and 1 thoracic. Nine had conventional subtype chordoma and 1 had chondroid subtype. Eight of the 10 patients had previous surgery, 6 had previous radiation therapy and 5 had 1-2 lines of prior systemic therapy, including one who received pembrolizumab. Pretreatment biopsies were obtained from 9 out of 10 patients and blood has been collected on all patients. Nine patients were evaluable for study outcomes. A total of 64 AEs (Grades 1-4) have been noted to date, with 6 events being classified as grade 3-4: nausea, facial pain, headache, and pulmonary embolism. Five serious adverse events (SAEs) were noted in patients on treatment: headache (2), asthma (1), myocarditis (1), and sepsis (1). The median PFS of the 9 evaluable patients was 21.4 weeks. At 4 months, 7 out of 9 patients were progression free (77.7%). At 6 months, 4 out of 9 patients remained progression free (44.4%) and had continued progression-free survival at 1 year. One out of 9 (9.1%) patients had a PR via RECIST 1.1. One patient discontinued treatment due to an adverse event (grade 1 myocarditis). Conclusions: This signal-finding study indicated that some patients with advanced chordomas can receive benefit with relatlimab in combination with nivolumab. The combination was well-tolerated and no new safety signals were found in this rare patient population. Correlative studies are ongoing. The study was closed for slow accrual. Clinical trial information: NCT03623854 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiang完成签到,获得积分10
1秒前
1秒前
缥缈幻悲完成签到,获得积分10
1秒前
王明月完成签到,获得积分10
2秒前
彭映梦完成签到 ,获得积分10
3秒前
小小酥被卷了完成签到,获得积分10
4秒前
科研通AI6.4的应助被obito采纳,获得10
6秒前
天真酸奶的应助被obito采纳,获得10
6秒前
CipherSage的应助被明亮绮菱采纳,获得10
6秒前
王明月发布了新的文献求助10
6秒前
Gyqqqq完成签到,获得积分10
7秒前
Owen的应助被feisun采纳,获得10
8秒前
8秒前
难过含烟完成签到 ,获得积分10
9秒前
likun完成签到,获得积分10
9秒前
10秒前
11秒前
科研通AI2S的应助被liquss采纳,获得10
11秒前
王木木要努力完成签到,获得积分10
11秒前
漫漫发布了新的文献求助10
11秒前
说谎的桔梗花完成签到,获得积分10
13秒前
13秒前
田様的应助被辛勤的振家采纳,获得10
14秒前
MARIO发布了新的文献求助10
15秒前
maoqiuzhao完成签到,获得积分10
15秒前
16秒前
充电宝的应助被庐州月采纳,获得10
16秒前
18秒前
XCZ_UHANGHI完成签到 ,获得积分10
19秒前
CodeCraft的应助被MADAO采纳,获得30
19秒前
19秒前
20秒前
21秒前
Tuniverse_发布了新的文献求助10
21秒前
lx的应助被科研通管家采纳,获得20
21秒前
21秒前
团子完成签到 ,获得积分10
22秒前
小蘑菇的应助被科研通管家采纳,获得10
22秒前
白敬亭发布了新的文献求助10
22秒前
coolru的应助被科研通管家采纳,获得10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621